Compare Stocks → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALPNNASDAQ:CBAYNASDAQ:IMNMNASDAQ:NXTCNASDAQ:SESN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALPNAlpine Immune Sciences$39.64+2.6%$31.98$6.71▼$42.88$2.53B1.131.30 million shs1.46 million shsCBAYCymaBay Therapeutics$32.48+0.0%$29.62$7.26▼$32.50$3.73B0.324.11 million shs8.36 million shsIMNMImmunome$24.68-3.3%$22.31$4.44▼$30.96$1.40B1.67589,994 shs1.26 million shsNXTCNextCure$2.23+14.9%$1.50$0.98▼$2.28$53.99M0.37556,740 shs1.02 million shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALPNAlpine Immune Sciences+2.56%-4.71%+10.23%+107.97%+391.20%CBAYCymaBay Therapeutics0.00%0.00%+0.50%+37.51%+271.20%IMNMImmunome-3.29%+2.24%-5.08%+130.65%+393.60%NXTCNextCure+15.25%+32.74%+42.49%+95.61%+45.75%SESNSesen Bio0.00%0.00%0.00%0.00%+1,900.00%Did You Get Your Free Bitcoin Yet? (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALPNAlpine Immune Sciences1.4855 of 5 stars2.51.00.00.03.74.20.0CBAYCymaBay Therapeutics3.7496 of 5 stars2.04.00.04.72.02.50.6IMNMImmunome0.621 of 5 stars1.54.00.00.02.61.70.0NXTCNextCure4.5535 of 5 stars3.53.00.04.42.91.71.3SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALPNAlpine Immune Sciences3.00Buy$38.86-1.97% DownsideCBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideIMNMImmunome3.00Buy$24.50-0.73% DownsideNXTCNextCure3.00Buy$6.00169.06% UpsideSESNSesen BioN/AN/AN/AN/ACurrent Analyst RatingsLatest NXTC, SESN, IMNM, ALPN, and CBAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/19/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.003/19/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$47.003/19/2024ALPNAlpine Immune SciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$33.00 ➝ $44.003/19/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$32.00 ➝ $50.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/15/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$44.002/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.50(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALPNAlpine Immune Sciences$58.88M44.13N/AN/A$5.64 per share7.03CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59IMNMImmunomeN/AN/AN/AN/A$1.37 per shareN/ANXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ASESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)CBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)IMNMImmunome-$36.90M-$1.81N/AN/AN/AN/A-191.23%-42.48%N/ANXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)SESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest NXTC, SESN, IMNM, ALPN, and CBAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALPNAlpine Immune SciencesN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALPNAlpine Immune SciencesN/A7.867.86CBAYCymaBay TherapeuticsN/A10.9610.96IMNMImmunomeN/A3.963.96NXTCNextCureN/A16.3816.38SESNSesen BioN/A6.106.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALPNAlpine Immune Sciences75.17%CBAYCymaBay Therapeutics95.03%IMNMImmunome44.58%NXTCNextCure42.65%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipALPNAlpine Immune Sciences42.30%CBAYCymaBay Therapeutics7.00%IMNMImmunome20.00%NXTCNextCure11.90%SESNSesen Bio3.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALPNAlpine Immune Sciences12665.55 million37.82 millionOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableIMNMImmunome3754.75 million43.80 millionOptionableNXTCNextCure8227.90 million24.58 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableNXTC, SESN, IMNM, ALPN, and CBAY HeadlinesSourceHeadlineDevin Haney: biography, record, fights and moreespn.com - December 9 at 5:50 PMTyson Fury: Biography, record, fights and moreespn.com - December 2 at 10:49 AMWhy the Tucker Carlson Biography Sales Are So Patheticthedailybeast.com - September 13 at 10:23 PMSesen Bio (NASDAQ: SESN)fool.com - August 4 at 6:23 PMJames McTeigue Biography & Moviestribute.ca - May 10 at 6:46 PMAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Biobizjournals.com - March 6 at 7:17 PMSesen Bio wins shareholder approval for Carisma mergermsn.com - March 2 at 1:30 PMSesen Bio Stockholders Approve Merger with Carisma Therapeuticsfinance.yahoo.com - March 2 at 1:30 PMSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Resultsfinance.yahoo.com - February 28 at 12:42 PMSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigationsbenzinga.com - February 24 at 9:19 PMLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carismafinance.yahoo.com - February 21 at 10:50 AMBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsstockhouse.com - February 17 at 8:59 PMLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meetingbusinesswire.com - February 16 at 4:47 PMSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Mergerfinance.yahoo.com - February 16 at 9:10 AMSesen Bio reaches deal with investor group, paving way for Carisma mergerendpts.com - February 15 at 2:11 PMLatest terms of Sesen Bio and Carisma merger appear to pass musterthepharmaletter.com - February 15 at 2:11 PM5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recapfinance.yahoo.com - February 15 at 9:11 AMBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsfinance.yahoo.com - February 15 at 9:11 AMSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupbizjournals.com - February 14 at 2:01 PMSesen gains 11% on amended terms for merger with Carismamsn.com - February 14 at 9:00 AMSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Mergerfinance.yahoo.com - February 14 at 9:00 AMSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agofinance.yahoo.com - February 6 at 10:17 AMSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Mergerfinance.yahoo.com - February 2 at 7:29 PMThe Petri Dish: Departed White House adviser returns to the Broadfinance.yahoo.com - February 2 at 9:28 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage immunotherapy company. It focuses on creating various immunotherapies through protein engineering technologies for autoimmune and inflammatory diseases. The company has strategic collaborations with biopharmaceutical companies and has a pipeline of clinical and preclinical candidates in development. Its pipeline includes Povetacicept, a dual B cell cytokine antagonist for multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways for treatment of severe inflammatory diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.CymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.ImmunomeNASDAQ:IMNMImmunome, Inc. operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.